# Cingulate Inc. (CING) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/CING
## Company Profile
- Ticker: CING
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 4.94 USD
- Market cap: 54280215.080000006 USD
- Last updated: 2026-08-05
## Business Overview
### Precision Timed Release Platform
Cingulate develops next-generation medicines using its Precision Timed Release platform. The technology uses multi-core tablets to deliver several precisely timed drug releases during the day, with the goal of extending therapeutic coverage and improving adherence.
### CTx-1301 ADHD Candidate
CTx-1301 is a once-daily, multi-core dexmethylphenidate hydrochloride tablet for attention-deficit/hyperactivity disorder. It is designed to provide rapid onset and efficacy throughout the active day and is being reviewed through the FDA’s 505(b)(2) pathway.
### 505(b)(2) Development Model
The regulatory strategy uses an established active pharmaceutical ingredient while seeking approval for a differentiated release profile and dosage form. This allows Cingulate to focus development on pharmacokinetics, duration of effect, manufacturing, and product-specific clinical performance.
### Commercial Readiness
Cingulate is preparing payer access, distribution, supply chain, artificial intelligence-supported marketing technology, commercial manufacturing, and a sales organization for CTx-1301. Launch remains dependent on FDA approval.
## Why The Stock Is Moving

As of Aug 5, 2026, CING closed up 0.82% at $4.94. No new same-company headline was identified in the current news window.

## Future Catalysts

- The FDA accepted the CTx-1301 NDA and assigned a PDUFA target action date of May 31, 2026.
- Cingulate is responding to FDA information requests related to manufacturing and CMC, with the outcome of the review determining potential approval and launch readiness.

## Recent News
- 2026-07-30 12:30 EST — [Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology](https://biopharmsignal.com/news/CING/cingulate-announces-publication-of-phase-3-adhd-trial-results-in-journal-of-chil-db095e97) — Source: Cingulate Inc.
- 2026-07-02 12:30 EST — [Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®](https://biopharmsignal.com/news/CING/cingulate-inc-nasdaq-cing-added-to-russell-3000e-1ee91267) — Source: Cingulate Inc.
- 2026-06-16 12:00 EST — [Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301](https://biopharmsignal.com/news/CING/cingulate-issued-first-u-s-patent-for-lead-adhd-asset-ctx-1301-15332cda) — Source: Cingulate Inc.
- 2026-06-02 12:00 EST — [Cingulate Receives Complete Response Letter from FDA for CTx-1301](https://biopharmsignal.com/news/CING/cingulate-receives-complete-response-letter-from-fda-for-ctx-1301-ef9797e1) — Source: Cingulate Inc.
- 2026-05-14 12:00 EST — [Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301](https://biopharmsignal.com/news/CING/cingulate-inc-reports-first-quarter-2026-financial-results-and-provides-an-updat-d516ef82) — Source: Cingulate Inc.